Treatment for dry eye by a long lasting P2Y2R agonist, diquafosol, was developed by Inspire Pharmaceuticals, Inc. and is currently in use in Japan and Korea (see Lau et al., 2014). Here, P2RY2 is linked to Keratoconjunctivitis sicca.